Capasso Planning Partners LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 33.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,030 shares of the company's stock after selling 1,001 shares during the quarter. Capasso Planning Partners LLC's holdings in Eli Lilly and Company were worth $1,568,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after buying an additional 60,306 shares during the period. WCM Investment Management LLC lifted its position in shares of Eli Lilly and Company by 14.9% during the 3rd quarter. WCM Investment Management LLC now owns 13,260 shares of the company's stock worth $11,639,000 after buying an additional 1,716 shares during the period. Everhart Financial Group Inc. raised its holdings in shares of Eli Lilly and Company by 14.1% in the third quarter. Everhart Financial Group Inc. now owns 5,433 shares of the company's stock valued at $4,813,000 after buying an additional 672 shares during the last quarter. Vestia Personal Wealth Advisors boosted its stake in shares of Eli Lilly and Company by 1.7% in the 3rd quarter. Vestia Personal Wealth Advisors now owns 767 shares of the company's stock valued at $680,000 after purchasing an additional 13 shares during the last quarter. Finally, Apollon Wealth Management LLC increased its stake in Eli Lilly and Company by 7.0% in the third quarter. Apollon Wealth Management LLC now owns 14,230 shares of the company's stock valued at $12,607,000 after purchasing an additional 936 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
LLY has been the topic of several research analyst reports. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price target on the stock. Bank of America restated a "buy" rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,009.72.
Read Our Latest Stock Report on LLY
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $823.95 on Wednesday. The firm has a market capitalization of $781.25 billion, a PE ratio of 70.36, a PEG ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The business's 50 day moving average is $828.77 and its 200-day moving average is $845.45.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Eli Lilly and Company announced that its board has approved a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
